
- Volume 0 0
Rebetol Oral Solution
Schering-Plough Corp (Kenilworth, NJ) has announced the launch of Rebetol (ribavirin USP) Oral Solution for use in combination with Intron A (interferon alfa- 2b, recombinant) Injection for treating pediatric chronic hepatitis C. The combination of Intron A and Rebetol is indicated for the treatment of patients 3 years of age and older with compensated liver disease previously untreated with alpha interferon. Rebetol Oral Solution represents a new formulation of ribavirin USP, developed specifically to meet the needs of pediatric patients. It comes in bubble-gum flavor. For more information, visit www.scheringplough. com.
Articles in this issue
over 21 years ago
Interface Speeds Up Prescription Fillingover 21 years ago
New Technologies Top Surveyover 21 years ago
Partnership Addresses Packaging Solutionsover 21 years ago
PDX Software Gets High Marksover 21 years ago
Polar Powder Cold Pak with Magnetic Therapyover 21 years ago
Seal•ONover 21 years ago
SaltAire Sinus Reliefover 21 years ago
Zim's Crack Creme Hand Sanitizerover 21 years ago
CoroWise Plant Sterolsover 21 years ago
CulturelleNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.